Phenotypes associated with this allele

• Allele Symbol: Tg(Vil-SLC3A2)HEMerl
• Allele Name: transgene insertion HE, Didier Merlin
• Allele ID: MGI:5433607
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
tg1	Tg(Vil-SLC3A2)HEMerl/0	involves: FVB/N	MGI:5433668

Genotype
MGI:5433668

tg1

• Allelic Composition: Tg(Vil-SLC3A2)HEMerl/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Abnormal morphology and decreased size of microvilli on the apical membrane of jejunal enterocytes in Tg(Vil-SLC3A2)HEMerl/0 mice

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:173946 )

• 5 of 19 mice die when mice treated with azoxymethane and DSS in mice chronically treated with DSS

digestive/alimentary system

rectal hemorrhage ( J:173946 )

• in DSS-treated mice

abnormal enterocyte morphology ( J:173946 )

abnormal cecum morphology ( J:173946 )

• dilated

abnormal small intestine morphology ( J:173946 )

• larger and longer than in wild-type mice

decreased small intestinal microvillus size ( J:173946 )

increased colon adenoma incidence ( J:173946 )

• mice treated with azoxymethane and DSS or chronically treated with DSS develop more and larger tumors than wild-type mice

diarrhea ( J:173946 )

• in untreated mice and mice treated with DSS

abnormal intestine physiology ( J:173946 )

• barrier dysfunction

abnormal enterocyte physiology ( J:173946 )

• increased cell survival in untreated mice

• however, apoptosis rates are normal in mice treated with azoxymethane and DSS

abnormal enterocyte proliferation ( J:173946 )

• increased proliferation in untreated mice and in mice treated with azoxymethane and DSS or chronically treated with DSS

colitis ( J:173946 )

• chronic focal colitis with crypt epithelial degeneration and loss with neutrophil infiltrates

increased susceptibility to induced colitis ( J:173946 )

• mice treated with DSS exhibit increased weight loss, rectal bleeding, diarrhea, colon shortening, crypt loss and inflammatory infiltration into the mucosa and submucosa compared with wild-type mice

neoplasm

increased colon adenoma incidence ( J:173946 )

• mice treated with azoxymethane and DSS or chronically treated with DSS develop more and larger tumors than wild-type mice

increased incidence of tumors by chemical induction ( J:173946 )

• mice treated with azoxymethane and DSS or chronically treated with DSS develop more and larger colonic adenomas than wild-type mice

increased tumor growth/size ( J:173946 )

• in mice treated with azoxymethane and DSS

growth/size/body

increased susceptibility to weight loss ( J:173946 )

• in DSS-treated mice

decreased body size ( J:173946 )

• slimmer than wild-type mice

homeostasis/metabolism

increased circulating tumor necrosis factor level ( J:173946 )

• in DSS-treated mice

increased susceptibility to xenobiotic induced morbidity/mortality ( J:173946 )

• 5 of 19 mice die when mice treated with azoxymethane and DSS in mice chronically treated with DSS

increased incidence of tumors by chemical induction ( J:173946 )

• mice treated with azoxymethane and DSS or chronically treated with DSS develop more and larger colonic adenomas than wild-type mice

immune system

colitis ( J:173946 )

• chronic focal colitis with crypt epithelial degeneration and loss with neutrophil infiltrates

increased susceptibility to induced colitis ( J:173946 )

• mice treated with DSS exhibit increased weight loss, rectal bleeding, diarrhea, colon shortening, crypt loss and inflammatory infiltration into the mucosa and submucosa compared with wild-type mice

increased circulating tumor necrosis factor level ( J:173946 )

• in DSS-treated mice

cardiovascular system

rectal hemorrhage ( J:173946 )

• in DSS-treated mice

cellular

abnormal enterocyte proliferation ( J:173946 )

• increased proliferation in untreated mice and in mice treated with azoxymethane and DSS or chronically treated with DSS